AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

AstraZeneca makes a deal to buy another biotech company, this one with a price tag that could reach $1 billion.

EsoBiotec announced it has entered into a definitive agreement to be acquired by AstraZeneca (AZN). The EsoBiotec Engineered NanoBody ...

AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion ...

AstraZeneca to buy in vivo cell therapy company, EsoBiotec for US$ 1billion: Cambridge, UK Tuesday, March 18, 2025, 10:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceu ...

AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company ...

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...